Cancer prognosis by type
Pro Research Analysisby 
Searched over 200M research papers
Cancer Prognosis by Type: Key Factors and Subtype Differences
Breast Cancer Prognosis by Subtype and Histology
Breast cancer prognosis varies greatly depending on molecular subtype and histological type. Subtypes defined by hormone receptor (HRc) and HER2 status show clear differences in survival outcomes. HRc(+)/HER2(−) breast cancers have the best 5-year breast cancer–specific survival (95.5%), followed by HRc(+)/HER2(+) (94.1%), HRc(−)/HER2(+) (89.3%), and HRc(−)/HER2(−), also known as triple-negative, which has the worst prognosis (83.1%) regardless of race, age, or stage . Subtype-specific gene expression signatures further improve risk stratification and prognosis prediction, especially for estrogen receptor positive (ER+) patients, and can guide more precise therapies .
Certain rare histological subtypes of breast cancer, such as mucinous, tubular, papillary, adenoid cystic, and cribriform carcinomas, are associated with excellent outcomes, with overall survival rates above 90% in some cases. For these favorable subtypes, systemic chemotherapy may not be necessary, especially in hormone receptor-positive, node-negative patients 710. Even within triple-negative breast cancers (TNBC), which are generally aggressive, some rare subtypes like adenoid cystic and secretory carcinoma have a relatively indolent course and favorable prognosis, suggesting that aggressive treatment may not always be required .
Cervical Cancer Prognosis by Histological Type
Cervical cancer prognosis is influenced by histological type and disease stage. Squamous cell carcinoma (SCC) is the most common and has a better prognosis compared to adenocarcinoma (AC) and adenosquamous carcinoma (ASC). Patients with AC and ASC have significantly poorer outcomes than those with SCC, especially in stage II and III disease. Additionally, among patients receiving chemoradiotherapy, those with AC have worse survival than those with SCC. These findings highlight the need for tailored treatment and follow-up based on histological type and stage .
Urothelial (Bladder) Cancer Prognosis by Molecular Subtype
Muscle-invasive urothelial cancer (bladder cancer) can be classified into basal, luminal, and p53-like molecular subtypes. The basal subtype is associated with the best survival outcomes, while the p53-like subtype has the worst prognosis, including a higher risk of bone metastases and chemoresistance. These molecular classifications are predictive of clinical outcomes and can help identify patients who may benefit most from specific chemotherapy regimens .
Prognosis Across Multiple Cancer Types: Deep Learning and Multi-Omics Approaches
Recent advances in deep learning and multi-omics data integration have improved the ability to predict prognosis across multiple cancer types. Deep learning models using histopathology images can provide significant prognostic information, even within specific cancer stages, and outperform traditional models based on stage, age, and sex alone . Similarly, integrating multi-omics data with deep learning methods can accurately identify cancer subtypes associated with survival differences across various cancers, offering more precise risk stratification than traditional statistical methods .
Actual Prognosis Versus Cancer-Specific Prognosis
It is important to distinguish between cancer-specific prognosis (relative survival) and actual prognosis (overall survival considering competing causes of death). For younger, healthier, and early-stage cancer patients, these measures are similar. However, for older or sicker patients, actual prognosis is often much lower due to the risk of dying from other causes. Stage at diagnosis remains the most powerful factor influencing prognosis across cancer types .
Conclusion
Cancer prognosis is highly dependent on cancer type, molecular and histological subtype, and stage at diagnosis. For breast, cervical, and urothelial cancers, specific subtypes and histologies are linked to markedly different outcomes, guiding treatment decisions. Advances in deep learning and multi-omics integration are enhancing prognostic accuracy across cancer types. Understanding both cancer-specific and actual prognosis is essential for informed clinical decision-making and patient counseling.
Sources and full results
Most relevant research papers on this topic